Press Releases for NVO

Press Releases
Paladin Reports Record Third Quarter 2009 Financial Results
Patient Education Summits to Address Special Challenges of Hemophilia Patients and Their Families
Dwayne Johnson, Novo Nordisk and the Entertainment Industry Foundation Educate Families about Healthy Living and Diabetes
Photos: Norditropin NordiFlex(R) 30 mg/3 mL Prefilled Pen Offers Children Needing a Larger Dose of Growth Hormone a Convenient Option
Novo Nordisk: Half-Yearly Report
Novo Nordisk Appoints Per Falk, M.D., Ph.D., as Vice President for Clinical, Medical and Regulatory Affairs for North America
Liraglutide Lowered Blood Sugar and Weight in African Americans With Type 2 Diabetes, Phase 3 Data Showed
Liraglutide Lowered Blood Sugar and Weight in African Americans With Type 2 Diabetes, Phase 3 Data Showed
NCDP Health Care Reform Recommendations Advocate for Diabetes Prevention, Treatment and Care
FDA Approves NovoLog(R) Labeling Update
Diabetes Advocates Call For National Strategy, Leadership to Reduce Diabetes and Advance Detection and Treatment
Novo Nordisk A/S -- Treasury Stock
Novo Nordisk Insulin Analogs Have Proven Safety Profiles
FDA issues advisory for Levemir insulin
Novo Nordisk Warns Customers About Stolen Insulin
Novo Nordisk Convenes Policy and Clinical Experts at Diabetes Media Summit
The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
Novo Nordisk: New study directly comparing insulin delivery devices shows that Next Generation FlexPen® has a significantly lower injection force than SoloStar® and KwikPen®
Americans Who Don't Know They Have Diabetes Incur $18 Billion in Health Expenses Each Year
Olympia Dukakis urges diabetes screening
Video: Academy Award(R) Winner Olympia Dukakis and Husband, Actor Louis Zorich, Encourage Older Adults to Ask.Screen.Know.
Photo: Levemir(R) Once-Daily Substantially Lowered Average Blood Sugar Levels of Patients with Type 2 Diabetes in TITRATE(R) Study
Novo Nordisk Named 'Best Place to Work in New Jersey'
Novo Nordisk A/S -- 1st Quarter Results
Indy Lights Racer Charlie Kimball Doesn't Let Diabetes Slow Him Down
AnalystChoice.Com Free CFA Opinion on NVO, WR, WRE and AB
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
Photos: Novo Nordisk Improved FlexPen(R) Now Available in the U.S.
Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts
Transaction in Own Shares - Feb 16 2009 9:54AM
Zacks #1 Rank Top Performers: LaBranche & Co., Open Text Corporation, Multi-Fineline Electronix, Gilead Sciences, Inc. And Novo Nordisk
Novo Nordisk Makes its Debut in FORTUNE's '100 Best Companies to Work For'
Photo Release -- Merrion Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion
VLST Corporation and Novo Nordisk Announce Collaboration Agreement to Develop Therapeutics for Autoimmune and Inflammatory Disorders
Research and Markets: This Essential Report on Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012 for the Republic of Korea is Now Available
Study Finds Cost of Diabetes in the United States Exceeds $217 Billion
Novo Nordisk Launches Levemir(R) Satisfaction Guarantee Program
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children - Nov 6 2008 2:28PM
FDA Approves Additional Indication for Norditropin(R) for Small for Gestational Age (SGA) in Children - Nov 4 2008 10:29AM
NASDAQ OMX Group Hosts Its First Middle East Investor Conference in Dubai to Provide Issuers With Access to Gulf Investors; Exchange Will Ring NASDAQ Opening Bell From Dubai On November 20
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide Is More Effective Than Exenatide in Treatment of Type 2 Diabetes
Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
Data From One-Year Liraglutide Phase 3 Study Published Online in The Lancet
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes - PR Newswire
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes - Market Wire
Emisphere Announces License Agreement With Novo Nordisk to Develop Oral Formulation of GLP-1 Receptor Agonists for Diabetes
/C O R R E C T I O N -- Novo Nordisk/
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
New Data From Head-to-Head Study Confirms Once-Daily Levemir(R) is as Effective as Glargine over a 24-Hour Period in Subjects with Type 2 Diabetes
Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
Novo Nordisk and Neose Announce Completion of Initial Phase 1 Clinical Trial of NN7128 (Long-Acting Factor VIIa)
FDA Approves NOVO NORDISK's NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors - Jun 2 2008 12:37AM
Leading Advocacy Groups Set National Diabetes Goal - Jun 2 2008 12:37AM
Neose and Novo Nordisk Expand Agreement
Neose Receives Milestone Payment From Novo Nordisk on Second Protein
Neose Receives Milestone Payment From Novo Nordisk